VIMTALABS Vimta Labs Q1 FY26 results (Apr–Jun 2025) and concall
Vimta Labs delivered a robust Q1 FY26, achieving its highest-ever quarterly revenue of INR993 million, a 31.4% YoY increase, driven by strong performance in pharmaceutical testing and research. Profitability metrics also saw significant gains, with EBITDA and PAT growing over 33% YoY. The company successfully navigated a US FDA inspection and announced a 1:1 bonus issue, reflecting strong operational and financial health. However, management foresees a temporary 1-2% margin compression due to new facility costs and rising HR expenses, and noted a flat domestic revenue trend.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 85 | 90 | 94 | 98 |
| EBITDA | 30 | 33 | 33 | 34 |
| Net profit | 15 | 22 | 18 | 19 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
